-
JAMES MOLLOYList Item 1
James Molloy is a Managing Director and Biotechnology and Specialty Pharmaceuticals Equity Research Analyst at A.G.P./Alliance Global Partners. He provides coverage of companies in several therapeutic categories in the biotechnology & pharmaceuticals sector, with a focus on immuno-oncology, central nervous system, cardiovascular, and anti-infective disorders.
Read More About James Molloy >>
-
YI CHEN PH.D., CFAList Item 2
Dr. Chen is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biotechnology and the pharmaceutical sectors. Dr. Chen’s research covers investment opportunities in the U.S. healthcare industry.
Read More About Yi Chen >>
-
ALEXANDER NOWAK, CFAList Item 3
Alexander Nowak, CFA joined Craig-Hallum Capital Group as a Senior Research Analyst in 2018 and focuses on diagnostics, life science tools and medical technology companies. Prior to joining Craig-Hallum, Alex was an assistant vice president and research analyst at Piper Jaffray. Alex received his BA in Finance from University of St. Thomas and is a CFA charterholder.
Read More About Alexander Nowak >>
Alimera Sciences Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Alimera Sciences Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Alimera Sciences Inc. or its management. Alimera Sciences Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
